Clinical Trial Search

Primary: Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban — 179.116; 122.145 ng/mL

Primary: Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement — 50.00; 71.43; 100.00…

Primary: Center for Epidemiological Studies-Depression Scale — 11.41; 12.43; 11.39; 9.06 units on scale — p=<.05

Primary: Percentage of Participants Who Died — 67.3; 69.6 percentage of participants

Primary: Percentage of Participants With a Clinically Significant Improvement in Fatigue After 4 Months of Tocilizumab Treatment — 63.3 Percentage of participants

Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02

Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2

Primary: Maximum and Minimum Diameters of the Inferior Vena Cava in Patients With Acute Kidney Injury — 1.8; 1.2 cm

Primary: Overall Colon Cleansing Procedure (ITT) Measured by the Total Ottawa Scale — 8.2; 4.2 score on a scale — p=<0.0001

Primary: Number of Participants With Major Bleeding Events ［Per International Society on Thrombosis and Homeostasis (ISTH) Definition］ or Clinically Relevant Non-major (CRNM)…

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within +/-1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range — 53.3 percentage…

Primary: WOMAC VAS (0:None -100:Extreme) Pain Subscale Score Change From Baseline — 30.15; 26.85 millimeter

Primary: Number of Serious Adverse Events (SAEs) — 13 number of SAEs

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 176; 70 Participants

Primary: To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer